Experimental weight-loss drug retatrutide was obtained with little or no medical oversight from two online providers and a Brooklyn corner shop, raising concerns about the safety of products being sold outside clinical trials.
Adam Yamaguchi ordered 20 milligrams of the drug, also known as Reta, from Reset Wellness, a clinic founded by a nurse practitioner. Although the website promised a health evaluation, the product arrived about a week later without him speaking to a healthcare professional.
He then bought retatrutide through Bodystreet Jupiter, a Florida gym, after confirming that he met its body mass index requirement. The website stated that a doctor would review his intake form, but the product was delivered two days later without a consultation.
Yamaguchi also found a poster advertising Reta for over-the-counter sale at a bodega in Brooklyn. He bought a vial labelled “Retatrutide” for 90 dollars, despite a warning stating: “Research use only, not for human consumption.”
Retatrutide is an experimental peptide drug being studied by Eli Lilly as a possible next-generation obesity treatment. It has not been approved by the US Food and Drug Administration and remains in clinical trials.
Dr Reshma Ramachandran, a Yale physician who has studied the use of peptides and weight-loss medicines, said it was “astounding” that the products were so accessible.
People using products labelled as retatrutide were effectively acting as “guinea pigs”, she said, because the drug had not yet been certified as safe and effective. Prescribing any medicine, she added, should involve a discussion of a patient’s medical history, potential risks and whether the treatment was suitable.
Tests raise concerns over retatrutide vials
University of Iowa research scientist Jason Galpin analysed the three samples obtained by Yamaguchi. The two purchased online were consistent with a basic standard he had created for retatrutide, although that standard was not the same as the drug used in Eli Lilly’s clinical trials.
The sample bought at the Brooklyn bodega appeared not to contain a peptide at all. “It does not look anything like a peptide,” Mr Galpin said.
Instead, testing identified phenylacetic acid, a compound Mr Galpin described as a filler and which is commonly found in fragrances and lip balms.
Further analysis by Carl Ross, director of development at the University of Iowa’s Center for Biocatalysis and Bioprocessing, found 13 colonies of bacteria in the sample.
Mr Ross warned that injecting material containing bacteria could lead to an infection. “We’re injecting bacteria under the skin where it could multiply,” he said. “It’s pretty terrifying.”
Dr Ramachandran said people buying such products could potentially make themselves very ill and called for greater oversight as access to unapproved drugs expands.
She said: “I am trying to be hopeful that there might be ways to regulate these platforms… like the horse is out of the barn and so we’re going to be trying to catch up to what’s our current reality of really easy access.”
Reset Wellness, Bodystreet Jupiter and INDR Labs were contacted for comment but had not responded.
An Eli Lilly spokesman said regulated manufacturers had to demonstrate quality and consistency “dose after dose”, unlike unregulated sellers. He warned that testing a single sample could not establish that other vials were sterile, stable or safe.
“Consumers are gambling with their health, with no way of knowing when a dangerous vial may arrive at their door,” the spokesman said.
